The 2019 ASTRO Research Workshop will debate the current data on the biology, physics and regulatory issues concerning oligometastatic disease and discuss the latest clinical trials.
View a detailed program.
One feature of many cancers which makes them deadly and difficult to treat is the development of pioneer cells, able to release from the primary tumor and move throughout the body using the lymphatic or vascular systems, or simply through direct extension into another organ. Such metastatic tumors are associated with a poorer prognosis and ultimately lead to cancer-associated death. Oligometastatic disease is as an intermediate state between localized and disseminated cancer. These small regions of metastasis nearby the tumor origination site are much more likely to be amenable to treatment than widely-distributed metastatic cancer. There is increasing interest in oligometastatic disease in both the academic and the wider cancer community, partly because of the long-term survival that can be achieved through multimodality treatment strategies for patients with oligometastatic cancer.
Local ablative therapies (such as surgery, radiofrequency ablation and radiation therapy) may play an important role in the treatment of oligometastatic cancer, particularly in delaying disease progression and increasing survival times. Stereotactic body radiation therapy (SBRT) has rapidly emerged as an effective and less toxic tool for the treatment of lung, liver, adrenal, brain and bone metastases. The ability of modern radiotherapy techniques to deliver potentially ablative doses to numerous organ sites throughout the body has allowed for the aggressive treatment of unresectable metastases.